• In a prospective study of aspirin therapy for 67 children with juvenile rheumatoid arthritis, we have found that (1) doses greater than 100 mg/kg/day of aspirin may be necessary to achieve therapeutic salicylate levels greater than 20 mg/dL; (2) no improvement in clinical remission rate is seen at salicylate levels greater than 30 mg/dL; (3) clinical toxicity to aspirin is of relatively low incidence (16%), and infrequently causes serious morbidity; (4) symptomatic SGOT elevations are common in the first three months after onset of therapy; and (5) these elevated SGOT levels generally return to normal despite continuation of therapy.
(Am J Dis Child 134:461-463, 1980)
Doughty RA, Giesecke L, Athreya B. Salicylate Therapy in Juvenile Rheumatoid Arthritis: Dose, Serum Level, and Toxicity. Am J Dis Child. 1980;134(5):461–463. doi:10.1001/archpedi.1980.02130170011005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: